
Subsidiary of AdRegeneer
Solutions
Nervous System Repair
Our therapy transforms the landscape of nervous system regeneration therapies. By integrating advanced epigenetic modulation, we directly promote remyelination, restoring lost neural functions with precision and safety.
While current approaches to neurodegenerative diseases focus largely on managing inflammation, our therapy breaks new ground by reprogramming glial cells at the transcriptional level and activating key repair pathways controlled by epigenetic factors such as histone deacetylase 2 (HDAC2). This technology unlocks new therapeutic possibilities, minimizes side effects, and accelerates the translation of breakthrough science into effective, remyelination-focused treatments.

Lesion
Repair
Advantages of Our Therapy

Restores Function, Epigenetic Precision, Low-Dose, High-Impact Treatment
Repair, not just relief, Targeted regeneration, Strong effect, Minimal dose​
Science
Innovative Methods
EpiGeneer is advancing a new era in nervous system regeneration by directly targeting remyelination. Our lead innovation centers on activating HDAC2 to promote myelin repair and restore neural function, going beyond conventional anti-inflammatory therapies. With our proprietary technology, we reprogram glial cells for repair at the transcriptional level, setting EpiGeneer apart in the field.
Our Milestones
Proven Success
Pre-Clinical
We have completed pre-clinical studies demonstrating the efficacy of our drug technologies on cell-based models and 4 different animal models
Publications
Our research has been published in highly recognized journals, expanding the impact of our findings within the scientific and biopharma communities
Production
We are excited to announce the start of GMP production and readiness for our minipig study, marking a key step forward in our partnership and drug development journey
Regulatory Milestone
Positive scientific advice from BfArM validating our clinical trial protocols
Strtegic Partnerships
We are engaged in ongoing discussions with leading transdermal patch companies and pharma companies to establish strategic partnerships and explore opportunities for joint investment
GMP Production
Clinical Trials
Go-to Market